Skip to content
Evonile Pharma Limited (formerly known as Novartis India Limited). Name changed with effect from 1 October 2026
Evonile_logo_withbyline
Menu Close
  • ABOUT US
    • Our Story
    • Board of Directors
  • THERAPEUTIC AREA
  • INVESTORS
    • Annual General Meeting
    • Charter Documents
    • CSR
    • Financials
    • Shareholder’s Information
    • Stock Exchange Disclosures
    • Transfer of Shares to IEPF Demat Account
    • Corporate Policies
    • Rights Issue
  • PHARMACOVIGILANCE
  • CONTACT US
  • ABOUT US
    • Our Story
    • Board of Directors
  • THERAPEUTIC AREA
  • INVESTORS
    • Annual General Meeting
    • Charter Documents
    • CSR
    • Financials
    • Shareholder’s Information
    • Stock Exchange Disclosures
    • Transfer of Shares to IEPF Demat Account
    • Corporate Policies
    • Rights Issue
  • PHARMACOVIGILANCE
  • CONTACT US
Evonile_logo_withbyline
Menu Close
  • ABOUT US
    • Our Story
    • Board of Directors
  • THERAPEUTIC AREA
  • INVESTORS
    • Annual General Meeting
    • Charter Documents
    • CSR
    • Financials
    • Shareholder’s Information
    • Stock Exchange Disclosures
    • Transfer of Shares to IEPF Demat Account
    • Corporate Policies
    • Rights Issue
  • PHARMACOVIGILANCE
  • CONTACT US
  • ABOUT US
    • Our Story
    • Board of Directors
  • THERAPEUTIC AREA
  • INVESTORS
    • Annual General Meeting
    • Charter Documents
    • CSR
    • Financials
    • Shareholder’s Information
    • Stock Exchange Disclosures
    • Transfer of Shares to IEPF Demat Account
    • Corporate Policies
    • Rights Issue
  • PHARMACOVIGILANCE
  • CONTACT US
  • ABOUT US
    • Our Story
    • Board of Directors
  • THERAPEUTIC AREA
  • INVESTORS
    • Annual General Meeting
    • Charter Documents
    • CSR
    • Financials
    • Shareholder’s Information
    • Stock Exchange Disclosures
    • Transfer of Shares to IEPF Demat Account
    • Corporate Policies
    • Rights Issue
  • PHARMACOVIGILANCE
  • CONTACT US
  • Toggle website search
sed

Stock Exchange Disclosures

Menu Close
  • Press Release
  • Board Meeting Notice
  • Buyback
  • Complaints
  • Corporate Governance Report
  • Disclosure under Regulation 30 of SEBILODR
  • Integrated Corporate Governance
  • Newspaper Publications
  • Open Offer
  • Other Stock Exchange Disclosures
  • Earnings Call
  • Investor / Analyst Calls
  • Reconciliation of Share Capital Audit Report
  • Related Party Transaction Report
  • Shareholding Pattern
  • Press Release
  • Board Meeting Notice
  • Buyback
  • Complaints
  • Corporate Governance Report
  • Disclosure under Regulation 30 of SEBILODR
  • Integrated Corporate Governance
  • Newspaper Publications
  • Open Offer
  • Other Stock Exchange Disclosures
  • Earnings Call
  • Investor / Analyst Calls
  • Reconciliation of Share Capital Audit Report
  • Related Party Transaction Report
  • Shareholding Pattern

Press Release

Press Release – November 03, 2026

View
evonile_logo_white
Evonile Pharma Limited is a healthcare-focused pharmaceutical company dedicated to delivering high-quality therapeutic solutions that addresses the evolving needs of patients and healthcare professionals.

About Us

  • Our Story
  • Board of Directors

Therapeutic Area

Pharmacovigilance

Contact Us

  • Pain management & Ortho
  • Women’s health
  • Nutrition & Wellness
  • Neurosciences
  • Transplantation & Immunology
  • Oncology & Specialty Care
  • Cardiovascular Care

Investors

  • Annual General Meetings
  • Charter Documents
  • CSR
  • Financials
  • Shareholder's Information
  • Stock Exchange Disclosures
  • Transfer of Shares to IEPF Demat Account
  • Corporate Policies
  • Terms of Use
  • Disclaimer
  • Privacy Policy